RBC Comments on Amgen (AMGN) Repatha Data

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/25/2026

1. RNG
2. DECK
3. WDC
4. BMY
5. BYD
6. SPOT
7. WCN
8. TSCO
9. BE
10. SPY

Go back to RBC Comments on Amgen (AMGN) Repatha Data

Sanofi, Regeneron: 18-Month Results of ODYSSEY LONG TERM Trial with Praluent(TM) (alirocumab) Published in The New England Journal of Medicine

March 15, 2015 11:15 AM EDT

Sanofi and Regeneron Announce 18-Month Results of ODYSSEY LONG TERM Trial with Praluent (TM) (alirocumab) Published in The New England Journal of Medicine

- Robust and consistent LDL-C lowering demonstrated with PraluentTM in largest, double-blind, placebo-controlled trial of a PCSK9 inhibitor to date -   - Fewer major cardiovascular events observed with PraluentTM in post hoc analysis -

PARIS and TARRYTOWN, N.Y., March 15, 2015... More

Amgen Publishes Safety Analysis Of Investigational Cholesterol-Lowering Medication Repatha™ (evolocumab) In The New England Journal of Medicine

March 15, 2015 11:00 AM EDT

THOUSAND OAKS, Calif., March 15, 2015 /PRNewswire/ -- Amgen (NASDAQ: AMGN) today announced one-year data from prespecified exploratory endpoints of adjudicated cardiovascular events in the Phase 2 (OSLER-1) and Phase 3 (OSLER-2) open-label extension studies of Repatha (evolocumab), a novel investigational low-density lipoprotein cholesterol (LDL-C)-lowering medication. These data were presented today at a Late-Breaking Clinical Trial session at the American College of Cardiology's 64th Annual Scientific Session (ACC.15) and published in the New England Journal of Medicine. A two-year analysis of Repatha safety and tolerability data from the longest proprotein convertase... More